← Back to Search

Hormone Therapy

Tamoxifen 20 mg for Tumors

Phase 2
Recruiting
Led By Jonathan Strosberg, MD
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No possibility of established treatments due to lack of access, risk of toxicities or without clinical indication. Patients who meet criteria for watchful waiting (low-dose disease and non-functioning NET) may be included.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 5 years
Awards & highlights

Study Summary

This trial tests whether tamoxifen can help treat patients with neuroendocrine tumors that have progressed despite positive estrogen or progesterone expression.

Eligible Conditions
  • Tumors
  • Neuroendocrine Tumors

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You cannot receive standard treatments due to limited access, potential side effects or not meeting medical requirements. Patients with low-level disease and non-functioning neuroendocrine tumors may still be eligible.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Disease control rate
Incidence of Treatment-related Adverse Events
Progression-free survival
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: TamoxifenExperimental Treatment1 Intervention
The participants will receive tamoxifen 20mg orally once daily with a glass of water. Each cycle will be defined for 42 days (6 weeks).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tamoxifen 20 mg
2013
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
537 Previous Clinical Trials
134,976 Total Patients Enrolled
1 Trials studying Tumors
9 Patients Enrolled for Tumors
Jonathan Strosberg, MDPrincipal InvestigatorMoffitt Cancer Center
4 Previous Clinical Trials
167 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA sanctioned a dosage of 20 mg for Tamoxifen?

"Tamoxifen 20 mg safety has been partially studied in Phase 2 trials. Therefore, Power estimates the medication's security to be a score of two on a scale from one to three."

Answered by AI

Are there any other experiments involving Tamoxifen 20 mg which have been conducted?

"Presently, 67 trials are running for Tamoxifen 20 mg. Of those studies, 22 have reached the Phase 3 stage. While Ann Arbor is the epicentre of these experiments, 7300 medical sites across America host them."

Answered by AI

Is this medical investigation presently seeking participants?

"Yes, the clinicaltrials.gov database indicates that this medical study is actively recruiting patients. Launched on November 13th 2019 and last updated in October 2022, it seeks to involve 15 participants at a single site."

Answered by AI

Could you please provide an estimate of the number of participants involved in this trial?

"Affirmative. Clinicaltrials.gov displays that this clinical trial, which was initially posted on November 13th 2019, is currently enrolling patients; 15 participants need to be recruited from one medical centre."

Answered by AI

What medical conditions is Tamoxifen 20 mg typically utilized to treat?

"Tamoxifen 20 mg is routinely prescribed for malignant neoplasms, but can also be utilized to address ovarian cancer and ovulation induction therapy among other high-risk conditions."

Answered by AI
~3 spots leftby Mar 2025